Cost-effectiveness analysis of irinotecan compared with best estimated infusional 5-FU regimen in patients with advanced colorectal cancer

被引：0
|
作者：
Neymark, N [1 ]
Adriaenssen, I [1 ]
Schmitt, C [1 ]
机构：
[1] ARCOS, Issy Les Moulineaux, France
来源：
MEDICAL DECISION MAKING | 1998年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：461 / 461
页数：1
相关论文
共 50 条
  • [1] Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer
    Schmitt, C
    Jolain, B
    Van Cutsem, E
    [J]. MEDICAL DECISION MAKING, 1998, 18 (04) : 484 - 484
  • [2] Cost-effectiveness of irinotecan in advanced colorectal cancer
    Trippoli, S
    Vaiani, M
    Cattel, F
    Messori, A
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (07) : 899 - 900
  • [3] Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU
    Iveson, TJ
    Hickish, T
    Schmitt, C
    Van Cutsem, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) : 1796 - 1804
  • [4] Cost-effectiveness of Irinotecan (CPT-11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5fluorouracil (5FU) containing regimen: Results based on a phase III trial
    Blijham, G
    Schmitt, C
    Aussage, P
    HenryLaunois, B
    Jolain, B
    Herait, P
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : OP4 - OP4
  • [5] Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.
    Schmitt, C
    Levy-Piedbois, C
    Frappé, M
    Durand-Zaleski, I
    Gruia, G
    Alakl, M
    Rougier, P
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [6] Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer.
    Seguru, A
    Fernández-Martos, C
    Aparicio, J
    Campos, JM
    Vicent, J
    Busquier, I
    Molins, C
    Guillem, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 156S - 156S
  • [7] Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents
    Schmoll, HJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A : S18 - S22
  • [8] Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer: after 5-FU failure
    Schmitt, C
    Blijham, G
    Jolain, B
    Rougier, P
    Van Cutsem, E
    [J]. ANTI-CANCER DRUGS, 1999, 10 (06) : 617 - 623
  • [9] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [10] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
12345